Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial.

Steward DL, Wilson KM, Kelly DH, Patil MS, Schwartzbauer HR, Long JD, Welge JA.

Otolaryngol Head Neck Surg. 2004 Oct;131(4):342-50.

PMID:
15467597
2.

Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.

Hall J, Dodd S, Durkin M, Sloan S.

Manag Care. 2002 Jul;11(7 Suppl):14-8.

3.

Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.

Park W, Hicks DM, Khandwala F, Richter JE, Abelson TI, Milstein C, Vaezi MF.

Laryngoscope. 2005 Jul;115(7):1230-8.

PMID:
15995512
5.

[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].

Maev IV, Balashova NN, Busarova GA.

Klin Med (Mosk). 2003;81(9):54-9. Review. Russian.

PMID:
14598594
6.

Effect of antisecretory therapy on atypical symptoms in gastroesophageal reflux disease.

Dore MP, Pedroni A, Pes GM, Maragkoudakis E, Tadeu V, Pirina P, Realdi G, Delitala G, Malaty HM.

Dig Dis Sci. 2007 Feb;52(2):463-8.

PMID:
17211695
7.

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.

Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ.

Aliment Pharmacol Ther. 1999 Jan;13(1):49-57. Erratum in: Aliment Pharmacol Ther 1999 Apr;13(4):567.

8.

A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.

Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, Tsuji T.

J Gastroenterol Hepatol. 2001 Jul;16(7):723-8.

PMID:
11446878
9.

Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.

Oda K, Iwakiri R, Hara M, Watanabe K, Danjo A, Shimoda R, Kikkawa A, Ootani A, Sakata H, Tsunada S, Fujimoto K.

Dig Dis Sci. 2005 Oct;50(10):1921-6.

PMID:
16187198
10.

Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.

Galmiche JP, Zerbib F, Ducrottè P, Fournet J, Rampal P, Avasthy N, Humphries TJ.

Aliment Pharmacol Ther. 2001 Sep;15(9):1343-50.

11.

Laryngopharyngeal sensory deficits in patients with laryngopharyngeal reflux and dysphagia.

Aviv JE, Liu H, Parides M, Kaplan ST, Close LG.

Ann Otol Rhinol Laryngol. 2000 Nov;109(11):1000-6.

PMID:
11089989
12.

Laryngopharyngeal reflux symptoms improve before changes in physical findings.

Belafsky PC, Postma GN, Koufman JA.

Laryngoscope. 2001 Jun;111(6):979-81.

PMID:
11404607
13.
14.

Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.

Johnson M, Guilford S, Libretto SE; Collaborative GP Research Group..

Curr Med Res Opin. 2002;18(5):303-10.

PMID:
12240793
15.

The comparison of an empiric proton pump inhibitor trial vs 24-hour double-probe Ph monitoring in laryngopharyngeal reflux.

Bilgen C, Ogüt F, Kesimli-Dinç H, Kirazli T, Bor S.

J Laryngol Otol. 2003 May;117(5):386-90.

PMID:
12803789
16.

Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.

Laheij RJ, Van Rossum LG, Jansen JB, Verheugt FW.

Aliment Pharmacol Ther. 2003 Jul 1;18(1):109-15.

17.

Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.

Sloan S.

Am J Gastroenterol. 2003 Mar;98(3 Suppl):S49-55. Review.

PMID:
12644031
18.

Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.

Newton M, Burnham WR, Kamm MA.

Eur J Gastroenterol Hepatol. 1998 Sep;10(9):753-8.

PMID:
9831269
20.
Items per page

Supplemental Content

Support Center